Empowered Funds LLC Makes New $2.04 Million Investment in Collegium Pharmaceutical, Inc. $COLL

Key Points

• Empowered Funds LLC acquired 56,504 shares of Collegium Pharmaceutical worth approximately $2.04 million, representing about 0.17% of the company.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and a $51.00 average price target, though several firms recently lowered their targets.
• Collegium exceeded quarterly expectations, reporting $1.92 EPS versus the $1.72 consensus estimate and revenue of $199.88 million, up 6.3% year over year.

Empowered Funds LLC bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 56,504 shares of the specialty pharmaceutical company's stock, valued at approximately $2,045,000. Empowered Funds LLC owned about 0.17% of Collegium Pharmaceutical at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Group One Trading LLC acquired a new position in Collegium Pharmaceutical during the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd boosted its position in Collegium Pharmaceutical by 205.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company's stock valued at $29,000 after buying an additional 427 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company's stock worth $47,000 after buying an additional 418 shares during the last quarter. Kemnay Advisory Services Inc. bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth $61,000. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company's stock worth $73,000 after buying an additional 2,190 shares in the last quarter.

Analyst Upgrades and Downgrades

COLL has been the subject of a number of research reports. Weiss Ratings cut Collegium Pharmaceutical from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday, August 11th. Needham & Company LLC reduced their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. Piper Sandler reaffirmed a "neutral" rating and issued a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Barclays dropped their target price on Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating for the company in a research report on Wednesday, August 19th. Finally, Zacks Research lowered Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $51.00.

Collegium Pharmaceutical Price Performance

COLL stock opened at $23.70 on Friday. The company has a fifty day moving average price of $32.12 and a 200-day moving average price of $34.37. The company has a market capitalization of $771.67 million, a P/E ratio of 19.11 and a beta of 0.72. Collegium Pharmaceutical, Inc. has a 52-week low of $23.64 and a 52-week high of $50.79. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The company had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same quarter in the previous year, the business earned $1.68 earnings per share. Collegium Pharmaceutical's revenue was up 6.3% compared to the same quarter last year. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 6.51 EPS for the current year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.